Believe it or not, energy efficiency is big business, and it's only getting bigger. HSBC estimates that the market could grow from $87 billion today to $245 billion per year by 2020. Numbers like that are hard to ignore, especially given that investors are by and large ignoring the energy efficiency opportunity right now.
One thing is for sure, though: Wall Street stalwarts such as Bank of America and Goldman Sachs are not.�In this video, Fool.com contributor Aimee Duffy looks at the recent energy investments at these banks, and what investors should take away from their specific initiatives.
Companies such as Goldman Sachs have been getting rich on trading floor tips for decades -- and for decades, those tips have been "for industry insiders only." But not anymore. Our top technology analyst recently infiltrated one of the finance world's most exclusive gatherings and left with three incredible investment opportunities, straight from the CEOs. These are profit-building strategies Main Street isn't meant to hear about -- so act now before someone shuts us up. Click if you want "industry insider" earnings -- now!
Hot Long Term Companies For 2015: Basic Energy Services Inc. (BAS)
Basic Energy Services, Inc. provides various well site services to oil and natural gas drilling and producing companies in the United States. Its Completion and Remedial Services segment provides pumping services, such as cementing, acidizing, fracturing, coiled tubing, nitrogen, and pressure testing; rental and fishing tools; snubbing services; thru-tubing; cased-hole wireline services; and underbalanced drilling in low pressure and fluid sensitive reservoirs. This segment operates 228 pressure pumping units. It also operates 14 coiled tubing units; 49 air compressor packages; 12 wireline units; and 34 snubbing units. The company�s Fluid Services segment offers oilfield fluid supply, transportation, storage, and construction services, which comprise the transportation of fluids and salt water; sale and transportation of fresh and brine water; rental of portable frac tanks and test tanks; operation of company-owned fresh water and brine source wells and non-hazardous wast ewater disposal wells; and preparation, construction, and maintenance of access roads, drilling locations, and production facilities. This segment owns and operates 955 fluid services trucks with a fluid hauling capacity of up to 150 barrels apiece. Its Well Servicing segment provides various services performed with a mobile well servicing rig and ancillary equipment, such as maintenance work, hoisting tools and equipment required by the operation, and plugging and abandonment services, as well as manufactures and sells workover rigs. It operates a fleet of 425 well servicing rigs. The company�s Contract Drilling segment employs drilling rigs and related equipment to penetrate the earth to a desired depth and initiate production. This segment owns and operates 12 land drilling rigs. The company was formerly known as Sierra Well Service, Inc. and changed its name to Basic Energy Services, Inc. in 2000. Basic Energy Services, Inc. was founded in 1992 and is based in Fort Wort h, Texas.
Advisors' Opinion:- [By Sara Murphy]
Basic Energy Services (NYSE: BAS ) derived more than a quarter of 2012 revenues from its fluid services unit. Its operations rely heavily on the legacy model of hauling water. Superior Energy Services (NYSE: SPN ) counts on its traditional fluid services offerings for about 20% of revenues.
10 Best Up And Coming Stocks To Invest In Right Now: ChemoCentryx Inc (CCXI)
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.
The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).
The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.
CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.
CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).
The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.
Advisors' Opinion:- [By CRWE]
ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.
- [By James E. Brumley]
The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.
10 Best Up And Coming Stocks To Invest In Right Now: The Advisory Board Company(ABCO)
The Advisory Board Company, together with its subsidiaries, engages in the provision of best practices research and analysis, business intelligence and software tools, and management and advisory services primarily in the United States. The company offers various programs and services, including best practices research services that focus on identifying best-demonstrated management practices, critiquing widely-followed but ineffective practices, and analyzing emerging trends in the health care and education industries; business intelligence and software tools, which allow members to pair their own operational data with the best practices insights; and management and advisory services programs for assisting member institutions to adopt and implement best practices to enhance performance. As of June 30, 2011, it provided 51 distinct membership programs to hospitals, health systems, colleges, universities, pharmaceutical and biotech companies, health care insurers, medical de vice and supply companies, and other educational institutions. The company was founded in 1979 and is headquartered in Washington, District of Columbia.
Advisors' Opinion:- [By Seth Jayson]
Advisory Board (Nasdaq: ABCO ) is expected to report Q4 earnings on May 9. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Advisory Board's revenues will grow 17.4% and EPS will grow 21.7%. - [By Jeremy Bowman]
What: Shares of The Advisory Board Company (NASDAQ: ABCO ) were up as much as 12% today, after the consulting firm beat top and bottom-line estimates in its quarterly report.
10 Best Up And Coming Stocks To Invest In Right Now: RF Micro Devices Inc.(RFMD)
RF Micro Devices, Inc. designs, develops, manufactures, and markets radio frequency (RF) components and compound semiconductor technologies in the United States and internationally. Its products enable mobility, as well as provide connectivity and support functionality in the cellular handsets, wireless infrastructure, wireless local area networks, cable television /broadband, Smart Energy/advanced metering infrastructure, and aerospace and defense markets. The company offers products that range from single-function components to highly integrated circuits and multi-chip modules (MCMs). Its integrated circuit products include gain blocks, low noise amplifiers, power amplifiers (PAs), receivers, transmitters, transceivers, modulators, demodulators, attenuators, switches, frequency synthesizers, and voltage-controlled oscillators (VCOs); MCM products consist of PA modules, switch-filter modules, active antenna products, VCOs, phase-locked loops, coaxial resonator oscillators , active mixers, variable gain amplifiers, hybrid amplifiers, power doublers, and optical receivers; and passive components consist of splitters, couplers, mixers, and transformers, as well as isolators and circulators. The company markets its products to original equipment manufacturers and original design manufacturers. RF Micro Devices, Inc. was founded in 1991 and is headquartered in Greensboro, North Carolina.
Advisors' Opinion:- [By MONEYMORNING]
Chipmaker Surges: We urged you buy shares of RF Micro Devices Inc. (Nasdaq: RFMD) in a report back on Dec. 26, reasoning that the maker of the so-called "radio-frequency" chips used in smartphones and other devices was poised for a rebound.
10 Best Up And Coming Stocks To Invest In Right Now: Addus HomeCare Corporation(ADUS)
Addus HomeCare Corporation provides a range of social and medical services to individuals in the home. The company serves individuals with special needs who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill, and disabled. It offers various health services that include personal care and assistance with activities of daily living, skilled nursing and rehabilitative therapies, and adult day care. The company?s Home and Community Services division offers assistance with bathing, grooming, dressing, personal hygiene and medication reminders, and other activities of daily living on a long-term, continuous basis, with an average duration of 20 months per consumer. Its Home Health Services division comprises physical, occupational, and speech therapy, as well as skilled nursing services, which are offered on a short-term, intermittent, or episodic basis to individuals recovering from an acute medical condition, with an average length of care of 80 days. The company?s payor clients include federal, state, and local government programs, such as Medicaid funded programs and Medicaid waiver programs; other state agencies and Medicare; and the Veterans Health Administration, commercial insurers, and private duty consumers. The company was formerly known as Addus Holding Corporation and changed its name to Addus HomeCare Corporation in September, 2006. Addus HomeCare Corporation was incorporated in 2006 and is headquartered in Palatine, Illinois.
Advisors' Opinion:- [By Monica Gerson]
Addus HomeCare (NASDAQ: ADUS) is projected to post its Q4 earnings at $0.25 per share on revenue of $68.07 million.
magicJack VocalTec (NASDAQ: CALL) is expected to post its Q4 earnings at $0.41 per share on revenue of $35.93 million.
10 Best Up And Coming Stocks To Invest In Right Now: Textainer Group Holdings Limited(TGH)
Textainer Group Holdings Limited, through its subsidiaries, engages in the purchase, ownership, management, leasing, and resale of a fleet of marine cargo containers worldwide. The company leases dry freight containers, as well as special-purpose containers to shipping lines, freight forwarding companies, and the United States military; manages a fleet of containers for and on behalf of the owners; and buys and resells used containers. It operates a fleet of approximately 1.6 million containers. The company was founded in 1979 and is headquartered in Hamilton, Bermuda. Textainer Group Holdings Limited is a subsidiary of Halco Holdings Inc.
Advisors' Opinion:- [By Joseph Hogue]
There is one particular shipping company of which investors are being especially fearful, to the point of hating it. I'm talking about Textainer Group Holdings (NYSE: TGH), a container leasing company with 2.6 million 20-foot equivalent containers, the largest fleet among its peers.
- [By Selena Maranjian]
Textainer (NYSE: TGH ) is in the business of leasing big containers for use in intermodal shipping. The shipping business can be expected to pick up as the global economy gets back on its feet. Textainer has recently been expanding into the leasing of tanks, as well. The company offers not only an appealing dividend yield of 4.9%, but it also has been raising that payout significantly, more than doubling it over the past five years. Its payout ratio is below 50%, too, suggesting plenty of room for further growth. Textainer's stock seems reasonably or attractively priced, too, with its forward P/E ratio of 8.0 below its five-year average of 8.5. Bears don't like its rising debt or negative free cash flow, though (which is partly a result of beefing up its supply of containers), but there's still a lot to like about it.
- [By Ong Kang Wei]
Another example of such a company is Textainer Group Holdings (TGH). Besides having a great container leasing service that is needed by shipping companies, like Digital Realty, it is the undisputed leader in its industry. Being the largest of its kind in the world, the company has a significant economies of scale benefit. This means that Textainer will get the lion's share of the profits, which is proven by the company's outsized profit margin of 42.10%.
10 Best Up And Coming Stocks To Invest In Right Now: Under Armour Inc.(UA)
Under Armour, Inc. develops, markets, and distributes performance apparel, footwear, and accessories for men, women, and youth primarily in the United States, Canada, and internationally. It offers products made from moisture-wicking synthetic fabrics designed to regulate body temperature and enhance performance regardless of weather conditions. The company provides its products in three fit types: compression (tight fitting), fitted (athletic cut), and loose (relaxed) extending across the sporting goods, outdoor, and active lifestyle markets. Its footwear offerings comprise football, baseball, lacrosse, softball, and soccer cleats; slides; performance training footwear; and running footwear. The company also provides baseball batting, football, golf, and running gloves, as well as licenses bags, socks, headwear, custom-molded mouth guards, and eyewear that are designed to be used and worn before, during, and after competition. Under Armour sells its products through retai l stores, as well as directly to consumers through its own retail outlets and specialty stores, Website, and catalogs. The company was founded in 1996 and is headquartered in Baltimore, Maryland.
Advisors' Opinion:- [By Rich Duprey]
Athletic apparel maker�Under Armour� (NYSE: UA ) �reported first-quarter earnings that�fell 50% year over year�but handily beat the Capital IQ consensus estimates�by $0.03 per share. Revenues surged 22% year over year, coming in well ahead of estimates.�
No comments:
Post a Comment